MEK inhibitors also showed a role in increased mitochondrial dependency to a much stronger degree in ACTL6A over-expressing tumors, suggesting their potential for treating a large subset of HNSCC tumors with increased ACTL6A expression. The gene discussed is MAP2K7; the disease is head and neck squamous cell carcinoma.